These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 28461071)

  • 1. Host oxidative folding pathways offer novel anti-chikungunya virus drug targets with broad spectrum potential.
    Langsjoen RM; Auguste AJ; Rossi SL; Roundy CM; Penate HN; Kastis M; Schnizlein MK; Le KC; Haller SL; Chen R; Watowich SJ; Weaver SC
    Antiviral Res; 2017 Jul; 143():246-251. PubMed ID: 28461071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection.
    Ashbrook AW; Lentscher AJ; Zamora PF; Silva LA; May NA; Bauer JA; Morrison TE; Dermody TS
    mBio; 2016 May; 7(3):. PubMed ID: 27222471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
    Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
    J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4'-Fluorouridine inhibits alphavirus replication and infection
    Yin P; May NA; Lello LS; Fayed A; Parks MG; Drobish AM; Wang S; Andrews M; Sticher Z; Kolykhalov AA; Natchus MG; Painter GR; Merits A; Kielian M; Morrison TE
    mBio; 2024 Jun; 15(6):e0042024. PubMed ID: 38700353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
    Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
    J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses.
    Varghese FS; Kaukinen P; Gläsker S; Bespalov M; Hanski L; Wennerberg K; Kümmerer BM; Ahola T
    Antiviral Res; 2016 Feb; 126():117-24. PubMed ID: 26752081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
    Lucas CJ; Davenport BJ; Carpentier KS; Tinega AN; Morrison TE
    J Virol; 2022 May; 96(9):e0006422. PubMed ID: 35416719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms.
    Ho YJ; Liu FC; Yeh CT; Yang CM; Lin CC; Lin TY; Hsieh PS; Hu MK; Gong Z; Lu JW
    Antiviral Res; 2018 Nov; 159():134-142. PubMed ID: 30300716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro Studies on The Inhibition of Replication of Zika and Chikungunya Viruses by Dolastane Isolated from Seaweed Canistrocarpus cervicornis.
    Cirne-Santos CC; de Souza Barros C; de Oliveira MC; Rabelo VW; Azevedo RC; Teixeira VL; Ferreira DF; de Palmer Paixão ICN
    Sci Rep; 2020 May; 10(1):8263. PubMed ID: 32427940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venezuelan equine encephalitis virus E1 protein interacts with PDIA6 and PDI inhibition reduces alphavirus production.
    Panny L; Akrhymuk I; Bracci N; Woodson C; Flor R; Elliott I; Zhou W; Narayanan A; Campbell C; Kehn-Hall K
    Antiviral Res; 2023 Apr; 212():105560. PubMed ID: 36822370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection.
    Albulescu IC; White-Scholten L; Tas A; Hoornweg TE; Ferla S; Kovacikova K; Smit JM; Brancale A; Snijder EJ; van Hemert MJ
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32191995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments.
    Varghese FS; Rausalu K; Hakanen M; Saul S; Kümmerer BM; Susi P; Merits A; Ahola T
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.
    Bouma EM; van de Pol DPI; Sanders ID; Rodenhuis-Zybert IA; Smit JM
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
    Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
    J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin Inhibits Chikungunya Virus Entry and Transmission.
    Ho YJ; Wang YM; Lu JW; Wu TY; Lin LI; Kuo SC; Lin CC
    PLoS One; 2015; 10(7):e0133511. PubMed ID: 26208101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
    Henß L; Beck S; Weidner T; Biedenkopf N; Sliva K; Weber C; Becker S; Schnierle BS
    Virol J; 2016 Aug; 13(1):149. PubMed ID: 27581733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice.
    Ashbrook AW; Burrack KS; Silva LA; Montgomery SA; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Nov; 88(21):12180-92. PubMed ID: 25142598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the chikungunya virus E1 glycoprotein domain II and hinge influence E2 conformation, infectivity, and virus-receptor interactions.
    Thannickal SA; Battini L; Spector SN; Noval MG; Álvarez DE; Stapleford KA
    J Virol; 2024 Jul; 98(7):e0067924. PubMed ID: 38842335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Members of the
    Ferreira AC; Reis PA; de Freitas CS; Sacramento CQ; Villas Bôas Hoelz L; Bastos MM; Mattos M; Rocha N; Gomes de Azevedo Quintanilha I; da Silva Gouveia Pedrosa C; Rocha Quintino Souza L; Correia Loiola E; Trindade P; Rangel Vieira Y; Barbosa-Lima G; de Castro Faria Neto HC; Boechat N; Rehen SK; Brüning K; Bozza FA; Bozza PT; Souza TML
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.